期刊文献+

良性前列腺增生的磁共振波谱与前列腺特异性抗原的相关性初步研究

Study of correlation between MRS and serum PSA in benign prostatic hyperplasia
下载PDF
导出
摘要 目的:分析良性前列腺增生患者的磁共振波谱(MRS)与血清总前列腺特异性抗原(T-PSA)、游离前列腺特异性抗原(F-PSA)浓度和F-PSA/T-PSA比值的相关性。方法:30例超声引导下穿刺活检或手术切除后证实的良性前列腺增生病人,在中央区设定兴趣区后利用三维磁共振波谱(3DMRS)测定各兴趣区(胆碱+肌酸)/枸橼酸盐〔(Cho+Cre)/Cit〕的比值,计算出每位患者(Cho+Cre)/Cit比值的平均值,与其血清T-PSA、F-PSA浓度和F-PSA/T-PSA比值进行相关性分析。结果:(Cho+Cre)/Cit比值和血清T-PSA、F-PSA、F-PSA/T-PSA均无明显相关性(r分别为0.187、-0.125、-0.360,P值分别为0.323、0.510、0.051)。结论:前列腺增生症患者的(Cho+Cre)/Cit与血清T-PSA、F-PSA浓度和F-PSA/T-PSA比值无明显线性关联。 Objective: To evaluate the linear correlation between MRS and serum PSA in benign prostatic hyperplasia (BPH). Methods: Thirty patients with benign prostatic hyperplasia verified by biopsy or postoperative pathology underwent 3D MRS examination and serum PSA assay. The average ratio of (Cho+ Cre)/Cit was measured in each patient. Linear correlations between the ratio of (Cho-Cre)/Cit and T-PSA, F-PSA, F-PSA/T-PSA were analyzed. Results: There was no significant correlation between the ratio of (Cho+Cre)/Cit and the T PSA, F-PSA, F-PSA/T-PSA(The value of r respectively were 0. 187, -0. 125, -0. 360, the value of P respectively were 0. 323, 0. 510, 0. 051). Conclusion: There is not obvi ous correlation between the ratio of (Cho+Cre)/Cit and the T PSA, F PSA, F-PSA/T-PSA in patients with benign prostate hyperplasia.
出处 《新疆医科大学学报》 CAS 2008年第8期1014-1016,共3页 Journal of Xinjiang Medical University
关键词 前列腺增生 前列腺特异性抗原 磁共振波谱 相关性 prostatic hyperplasia prostate specific antigen magnetic resonance spectroscopy correlation
  • 相关文献

参考文献6

二级参考文献38

  • 1王继琛,高玉洁,蒋学祥,李松年,刘赓年.前列腺癌的MRI诊断与分期[J].中华放射学杂志,1996,30(11):741-744. 被引量:27
  • 2[1]Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7 cm3) spatial resolution[J]. Radiology, 1996, 198(3): 795-805.
  • 3[2]Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostate hyperplasia and normal prostate zone: detection via localized proton spectroscopy[J]. Urology, 1995,45(3):459-466.
  • 4[3]Ackerstaff E, Pflug BR, Nelson SJ, et al. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent transformation of prostatic epithelial cells[J]. Cancer Research, 2001, 61(9): 3599-3603.
  • 5[4]Cornel EB, Smits GAHJ, Oosterhof GON, et al. Characterization of human prostate cancer benign prostate hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy[J]. J Urol,1993,150(6): 2019-2024.
  • 6[6]Nadji M, Tallei LZ, Castro A, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms[J]. Cancer, 1981,48(5):1229-1232.
  • 7[7]Mueller-Lisse, UG, Mueller-Lisse UL, Haller S, et al. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis[J]. Journal of Computer Assisted Tomography, 2002, 26(3):432-437.
  • 8[8]Benson MC, Wang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer[J]. J Urol, 1992, 147(3):815-816.
  • 9[9]Garcia-Segura JM, Sanchez-Chapado M, Ibarburen C, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology[J]. Magnetic Resonance Imaging, 17(5):755-765.
  • 10[13]Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate-specific antigen cutoffs for early detection of prostate-cancer-receiver operating characteristic curves[J]. J Urol, 1994, 152(6):2037-2042.

共引文献156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部